State of Wyoming Makes New Investment in DaVita Inc. $DVA

State of Wyoming acquired a new stake in shares of DaVita Inc. (NYSE:DVA) during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm acquired 2,968 shares of the company’s stock, valued at approximately $519,000.

A number of other hedge funds have also recently bought and sold shares of DVA. Parcion Private Wealth LLC bought a new position in shares of DaVita during the third quarter valued at about $226,000. Asset Management One Co. Ltd. boosted its holdings in DaVita by 28.0% during the third quarter. Asset Management One Co. Ltd. now owns 1,675 shares of the company’s stock worth $293,000 after purchasing an additional 366 shares during the last quarter. Viewpoint Investment Partners Corp grew its position in DaVita by 21.4% in the 3rd quarter. Viewpoint Investment Partners Corp now owns 1,700 shares of the company’s stock worth $297,000 after purchasing an additional 300 shares in the last quarter. Apollon Wealth Management LLC grew its position in DaVita by 7.2% in the 3rd quarter. Apollon Wealth Management LLC now owns 2,078 shares of the company’s stock worth $363,000 after purchasing an additional 140 shares in the last quarter. Finally, Sterling Capital Management LLC increased its stake in DaVita by 104.2% in the 3rd quarter. Sterling Capital Management LLC now owns 9,140 shares of the company’s stock valued at $1,599,000 after buying an additional 4,665 shares during the last quarter. 90.12% of the stock is owned by hedge funds and other institutional investors.

DaVita Stock Performance

NYSE DVA opened at $185.37 on Tuesday. DaVita Inc. has a 52-week low of $101.00 and a 52-week high of $247.49. The company has a 50-day simple moving average of $181.58 and a 200 day simple moving average of $176.90. The company has a market capitalization of $11.83 billion, a PE ratio of 13.65, a price-to-earnings-growth ratio of 0.48 and a beta of 0.80.

DaVita (NYSE:DVA) last released its earnings results on Thursday, October 29th. The company reported $3.82 earnings per share for the quarter, beating analysts’ consensus estimates of $3.57 by $0.25. The firm had revenue of $3.58 billion for the quarter, compared to analysts’ expectations of $3.52 billion. DaVita had a net margin of 6.05% and a negative return on equity of 217.63%. The company’s quarterly revenue was up 4.6% on a year-over-year basis. During the same period in the previous year, the company earned $2.51 earnings per share. As a group, analysts forecast that DaVita Inc. will post 14.74 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have commented on DVA shares. Raymond James Financial set a $220.00 target price on shares of DaVita in a research report on Friday, August 7th. Barclays decreased their price target on DaVita from $224.00 to $216.00 and set an “equal weight” rating for the company in a research report on Monday. Wall Street Zen lowered DaVita from a “buy” rating to a “hold” rating in a report on Saturday. TD Cowen boosted their price objective on DaVita from $220.00 to $228.00 and gave the stock a “buy” rating in a research report on Monday. Finally, Truist Financial reduced their price objective on DaVita from $250.00 to $215.00 and set a “hold” rating for the company in a research note on Friday, August 7th. Four research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $235.86.

About DaVita

DaVita Inc (NYSE: DVA) is a health care services company focused on kidney care. Through its DaVita Kidney Care business, the company provides outpatient dialysis treatments for people with chronic kidney failure, including in-center hemodialysis, home dialysis and related clinical support services.

DaVita also offers integrated kidney care programs intended to support patients across the stages of chronic kidney disease. Its services may include care coordination, disease management, education, transplant support and other services designed to improve clinical outcomes and help manage the needs of patients with complex kidney conditions.

The company operates a network of dialysis centers and related facilities in the United States and serves patients in select international markets.